BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer

PHASE2/PHASE3TerminatedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

August 7, 2025

Conditions

Endometrial Cancer

Interventions

DRUG

carboplatin

the usage and dosage should be determined by the investigator

DRUG

Paclitaxel

the usage and dosage should be determined by the investigator

DRUG

Recombinant humanized anti-PD-1 monoclonal antibody injection

Strength 100 mg/4 mL, intravenous drip, recommended dose 300 mg, administered every 3 weeks (21 days) (Q3W).

Trial Locations (1)

Affiliated Cancer Hospital of Chongqing University, Chongqing